An intellectually active lifestyle—in other words, the so-called cognitive reserve—has a protective effect on the progression and severity of the symptoms of motor, cognitive and psychiatric ...

Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...

UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

An intellectually active lifestyle - in other words, the so-called cognitive reserve - has a protective effect on the ...

Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several ...

Qure has reached an agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130, its gene therapy treatment aimed at Huntington’s disease.

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease ...

Conventional investigations of the genetic contributors to Alzheimer's disease (AD) risk and progression have ignored the role of the X-chromosome, primarily due to technical analysis limitations.

Its potential in Huntington's disease emerged thanks to an AI drug screening platform operated by SOM, which is used to identify existing drugs that can be repurposed for use in new indications.

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...